Overview

Role of Pepsin Assay in Wheezy Infants

Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
0
Participant gender:
All
Summary
Wheezy infants were tested for gastro-esophageal reflux disease (GERD) using combined multiple channel intraluminal impedance-pH (MII-pH), esophagogastroduodenoscope (EGD), lipid laden macrophage index and BAL pepsin. Wheezy infants with abnormal MII-pH or reflux esophagitis were given domperidone and omeprazole then re-evaluated for symptoms control and exacerbations recurrence.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Mansoura University Children Hospital
Treatments:
Domperidone
Omeprazole
Criteria
Inclusion Criteria:

- Infants with physician documented 3 attacks of wheezing episodes over the last 6
months or persistent wheeze over the last one month

Exclusion Criteria:

- Wheezy infants with atopy (allergic rhino-conjunctivitis or eczema), prematurity (less
than 34 weeks), abnormal neurological examination, congenital heart diseases, airspace
opacity on chest radiography, tracheal-bronchial malformations, immune deficiency and
anatomical esophageal or gastric malformations